drugset / Trial / NCT05033431
Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants
Non-randomizedParallel-groupOpen-labelOther
Summary
This is a Phase I, single-centre, open-label, parallel-group, single dose study to evaluate the pharmacokinetics, safety and tolerability of Brazikumab in healthy male and female Chinese participants and healthy male and female White participants.
Timeline
- Start
- 2021-10-11
- Primary completion
- 2022-10-12
- Completion
- 2022-10-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brazikumab | Unknown | — | Intravenous |
Indications
No indication recorded.